Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1995 Sep 11;23(17):3600–3602. doi: 10.1093/nar/23.17.3600

Synthesis of 3H-labeled nucleoside-methyl[CT3]phosphonamidite and incorporation into methylphosphonate oligonucleotides for biodistribution and biostability studies.

M M Vaghefi 1, R C Fazio 1, K M Young 1, W B Marvin 1
PMCID: PMC307243  PMID: 7567475

Full text

PDF
3600

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595–7599. doi: 10.1073/pnas.88.17.7595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chen T. L., Miller P. S., Ts'o P. O., Colvin O. M., Chem T. L. Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single i.v. injection in mice. Drug Metab Dispos. 1990 Sep-Oct;18(5):815–818. [PubMed] [Google Scholar]
  3. Goodarzi G., Watabe M., Watabe K. Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharm Drug Dispos. 1992 Apr;13(3):221–227. doi: 10.1002/bdd.2510130308. [DOI] [PubMed] [Google Scholar]
  4. Hogrefe R. I., Reynolds M. A., Vaghefi M. M., Young K. M., Riley T. A., Klem R. E., Arnold L. J., Jr An improved method for the synthesis and deprotection of methylphosphonate oligonucleotides. Methods Mol Biol. 1993;20:143–164. doi: 10.1385/0-89603-281-7:143. [DOI] [PubMed] [Google Scholar]
  5. Hogrefe R. I., Vaghefi M. M., Reynolds M. A., Young K. M., Arnold L. J., Jr Deprotection of methylphosphonate oligonucleotides using a novel one-pot procedure. Nucleic Acids Res. 1993 May 11;21(9):2031–2038. doi: 10.1093/nar/21.9.2031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Inagaki M., Togawa K., Carr B. I., Ghosh K., Cohen J. S. Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition. Transplant Proc. 1992 Dec;24(6):2971–2972. [PubMed] [Google Scholar]
  7. Milligan J. F., Jones R. J., Froehler B. C., Matteucci M. D. Development of antisense therapeutics. Implications for cancer gene therapy. Ann N Y Acad Sci. 1994 May 31;716:228–241. doi: 10.1111/j.1749-6632.1994.tb21715.x. [DOI] [PubMed] [Google Scholar]
  8. Milligan J. F., Matteucci M. D., Martin J. C. Current concepts in antisense drug design. J Med Chem. 1993 Jul 9;36(14):1923–1937. doi: 10.1021/jm00066a001. [DOI] [PubMed] [Google Scholar]
  9. Pierga J. Y., Magdelenat H. Applications of antisense oligonucleotides in oncology. Cell Mol Biol (Noisy-le-grand) 1994 May;40(3):237–261. [PubMed] [Google Scholar]
  10. Sands H., Gorey-Feret L. J., Cocuzza A. J., Hobbs F. W., Chidester D., Trainor G. L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994 May;45(5):932–943. [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES